REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Brokerages

REGENXBIO Inc. (NASDAQ:RGNX) has received a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $35.27.

RGNX has been the subject of several research analyst reports. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Morgan Stanley reiterated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. Chardan Capital reissued a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. Raymond James reiterated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $35.00 price target on shares of REGENXBIO in a research note on Wednesday, December 11th.

Institutional Trading of REGENXBIO

A number of institutional investors have recently made changes to their positions in RGNX. FMR LLC lifted its position in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC lifted its holdings in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 2,200 shares during the period. GAMMA Investing LLC boosted its stake in shares of REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 3,720 shares during the period. Finally, Arizona State Retirement System increased its position in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 1,997 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Trading Down 1.1 %

Shares of REGENXBIO stock opened at $7.77 on Monday. REGENXBIO has a 12-month low of $7.14 and a 12-month high of $28.80. The company has a market cap of $384.96 million, a P/E ratio of -1.54 and a beta of 1.28. The company’s fifty day simple moving average is $9.07 and its two-hundred day simple moving average is $10.77.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.